China Contract Research Organization(CRO) Industry Report, 2017-2021
  • Oct.2017
  • Hard Copy
  • USD $2,900
  • Pages:110
  • Single User License
    (PDF Unprintable)       
  • USD $2,700
  • Code: ZLC058
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,100
  • Hard Copy + Single User License
  • USD $3,100

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the development of new drugs assisted by CRO firms in recent years, stimulating the progression of global CRO industry which had a market size of USD31.7 billion in 2016.

There are more than 1,100 CRO companies around the world, led by QuintilesIMS, Covance, inVentiv Health, Charles River, Parexel, PPD, ICON and WuXi AppTec. Global top10 CRO firms hold a combined 45% or so market share for now.


China’s great competitive edge over the developed countries in pharmaceutical R&D cost has attracted several large international pharmaceutical companies to build dozens of R&D centers here and fueled the development of CRO industry in China. With the scale of about RMB46.2 billion in 2016, the CRO industry in China will maintain a rapid growth rate over the next five years, hitting an estimated RMB116.5 billion in 2021, driven by pharmaceutical companies’ more spending on R&D, an increase in the number of new drugs approved and favorable policies.

Leading Chinese CRO companies include WuXi AppTec, Pharmaron, Shanghai Medicilon, Shanghai ChemPartner, Hangzhou Tigermed Consulting, and JOINN Laboratories. WuXi AppTec is one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs with the strongest R&D strength and the largest (domestically) and a leading (globally) small-molecule pharmaceutical R&D service business. It occupied about 2% of the world’s CRO market and 9.5% of the Chinese CRO market in 2016.


The CRO industry in China will present the following three trends:

1) Pharmaceutical enterprises represented by AvvVie, Novartis, GSK and Eli Lilly and Company have closed or are about to close or sell their R&D centers in China, and will rely more on CRO enterprises for new drug research activities. This will promote the development of CRO industry and be conducive to local CRO enterprises.

2) As the world economy picks up, pharmaceutical enterprises increase their R&D budget gradually, bringing global pharmaceutical R&D spending up to an estimated USD160 billion in 2021, including USD29.2 billion in China. This will drive the development of CRO industry from supply side.

3) Bright prospects of CRO industry and favorable policies in China have attracted enterprises represented by Dian Diagnostics, Xinjiang Baihuacun, Quantum Hi-Tech (China) Biological, and Xiamen Academy Of Building Research Group into the field, to some extent, promoting the development of CRO industry in China.

China Contract Research Organization (CRO) Industry Report, 2017-2021 highlights the followings:
20120114.gifOverview of CRO industry (development course/background, market size, competitive landscape, etc.);
20120114.gifOverview of CRO industry in China (development environment/status quo, market size, competitive landscape, development trends, etc.);
20120114.gifTen Chinese and six foreign companies (operation, revenue structure, gross margin, R&D investment, etc.)

1 Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2 Evolution of Global CRO Industry
2.1 Development History
2.2 Development Background
2.3 Market Size
2.4 Competitive Landscape

3 Evolution of Chinese CRO Industry
3.1 Development Environment
3.1.1 Regulatory Environment
3.1.2 Policy Environment 
3.1.3 Industrial Environment
3.2 Status Quo
3.3 Market Size
3.4 Competitive Pattern
3.5 Development Trends
3.5.1 Transnational Pharmaceutical Companies Shut Down and Have a Clearance Sale of Their Research Centers in China, which Favors Local Chinese Companies
3.5.2 New Drug Approvals Increase and R&D Expenses Grow, Laying a Foundation for the Development of CRO Industry
3.5.3 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
3.5.4 Favorable Policies and Capital Promote the Development of Local Chinese Companies
3.5.5 Good Prospects Attract the Enterprises’ Access into CRO Industry

4 Major Chinese Companies
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Expenditure
4.1.6 Major Customers
4.1.7 CRO Business
4.1.8 Prospects
4.2 Hangzhou Tigermed Consulting Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Expenditure
4.2.6 Prospects
4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Expenditure
4.3.6 Prospects
4.4 Shanghai Medicilon Inc.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Expenditure
4.4.6 Major Customers
4.4.7 Prospects
4.5 Porton Fine Chemical Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D Expenditure
4.5.6 Prospects
4.6 JOINN Laboratories, Inc. 
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Expenditure
4.6.6 Major Customers
4.6.7 Prospects
4.7 Pharmaron
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Expenditure
4.7.6 Major Customers
4.7.7 Prospects
4.8 Obio Technology (Shanghai) Corp., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Expenditure
4.8.6 Major Customers
4.8.7 Prospects
4.9 Asymchem Laboratories Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R&D Expenditure
4.9.6 Major Customers
4.9.7 Prospects
4.10 Shanghai ChemPartner Co., Ltd.
4.10.1 Profile
4.10.2 Primary Business
4.10.3 Revenue Structure
4.10.4 Major Customers
4.10.5 Developments

5 Major Foreign Companies
5.1 LabCorp
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 CRO Business
5.1.5 Development in China
5.2 QuintilesIMS
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development in China
5.3 Parexel
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Development in China
5.6 inVentiv Health
5.6.1 Profile
5.6.2 Development in China

Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Corresponding Relationship between New Drug R & D Process, New Drug R & D Discipline and CRO Services 
Global Pharmaceutical Market Size, 2012-2021E 
Global Pharmaceutical Market Size (by Type), 2012-2021E
Global Pharmaceutical Market Size (by Region), 2012-2021E
Global Pharmaceutical R & D Investment, 2012-2021E 
Scale and YoY Growth of Global CRO Industry, 2011-2016 
Scale and YoY Growth of Global CRO Industry, 2016-2021E
Scale and YoY Growth of Global CMO/CDMO Industry, 2011-2016 
Scale and YoY Growth of Global CMO/CDMO Industry, 2016-2021E
Comparison between Global Major CRO Companies
Market Share of Global Major CRO Companies, 2014-2016
M&A Cases of Global Major CRO Companies 
Policies on China’s CRO Industry, 2010-2017   
China’s Pharmaceutical Market Size and % of the Global Market, 2012-2021E
China’s Pharmaceutical Market Size (by Type), 2012-2021E
China’s Pharmaceutical R & D Investment and Its Global Share, 2012-2021E
Development Course of China CRO Industry 
Pharmaceutical R & D Cost Comparison between China and Developed Countries
R & D Centers of Multinational Pharmaceutical Companies in China, 2001-2016
Scale and YoY Growth of China’s CRO Industry, 2011-2016
Scale and YoY Growth of China’s CRO Industry, 2016-2021E
Scale and YoY Growth of China’s CMO/CDMO Industry, 2011-2016 
Scale and YoY Growth of China’s CMO/CDMO Industry, 2016-2021E 
Layout of Major Global CRO Companies in Asia
Comparison between Major CRO Companies in China
China’s CRO Market Share (by Company), 2016
Revenue Comparison between Major CRO Companies in China, 2014-2016
Net Income Comparison between Major CRO Companies in China, 2014-2016
Listing of Local Chinese CRO Companies
Layout of Chinese Companies in CRO, 2015-2017
Main Business Classification of Wuxi AppTec  
Revenue and Net Income of Wuxi AppTec, 2014-2017
Operating Revenue of Wuxi AppTec (by Business), 2014-2017
Operating Revenue Structure of Wuxi AppTec (by Business), 2014-2017
Operating Revenue of Wuxi AppTec (by Region), 2014-2017
Operating Revenue Structure of Wuxi AppTec (by Region), 2014-2017
Gross Margin of Wuxi AppTec, 2014-2017
Operating Revenue and Gross Margin of Wuxi AppTec (by Business), 2014-2017
R & D Expenditure of Wuxi AppTec and % of Total Revenue, 2014-2017
Investment Projects of Wuxi AppTec by Raising Funds via IPO
Wuxi AppTec’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2017
CRO Revenue of Wuxi AppTec (by Business), 2014-2017
CRO Gross Margin of Wuxi AppTec (by Business), 2014-2017
Revenue and Net Income of Wuxi AppTec, 2016-2021E
Revenue and Net Income of Hangzhou Tigermed Consulting, 2013-2017
Revenue of Hangzhou Tigermed Consulting (by Business), 
Revenue Structure of Hangzhou Tigermed Consulting (by Business), 2014-2017
Revenue of Hangzhou Tigermed Consulting (by Region), 2014-2017
Revenue Structure of Hangzhou Tigermed Consulting (by Region), 2014-2017
Gross Margin of Hangzhou Tigermed Consulting (by Business), 2014-2017
R & D Expenditure of Hangzhou Tigermed Consulting and % of Total Revenue, 2013-2017
Jietongtairui’s Financial Data, 2014-2015
Expansion of Hangzhou Tigermed Consulting, 2004-2017 
Revenue and Net Income of Hangzhou Tigermed Consulting, 2016-2021E  
Revenue and Net Income of Guangzhou Boji Medical Biotechnological, 2014-2017  
Revenue of Guangzhou Boji Medical Biotechnological (by Business), 2014-2017 
Gross Margin of Guangzhou Boji Medical Biotechnological (by Business), 2014-2017
R & D Expenditure of Guangzhou Boji Medical Biotechnological and % of Total Revenue, 2014-2017 
Progress of Investment Projects of Guangzhou Boji Medical Biotechnological by Raising Funds via IPO by H1 2017 
Revenue and Net Income of Guangzhou Boji Medical Biotechnological, 2016-2021E  
Revenue and Net Income of Shanghai Medicilon, 2014-2016
Revenue of Shanghai Medicilon (by Business), 2014-2016 
Revenue Structure of Shanghai Medicilon (by Business), 2014-2016
Revenue of Shanghai Medicilon (by Region), 2014-2016
Gross Margin of Shanghai Medicilon (by Business), 2014-2016 
R & D Expenditure of Shanghai Medicilon and % of Total Revenue, 2014-2016
Investment Projects of Shanghai Medicilon by Raising Funds via IPO, 2017
Shanghai Medicilon’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2016 
Revenue and Net Income of Shanghai Medicilon, 2016-2021E
Revenue and Net Income of Porton Fine Chemical, 2014-2017
Revenue of Porton Fine Chemical (by Business), 2014-2017
Revenue Structure of Porton Fine Chemical (by Business), 2014-2017
Revenue of Porton Fine Chemical (by Region), 2014-2017
Revenue Structure of Porton Fine Chemical (by Region), 2014-2017
Gross Margin of Porton Fine Chemical (by Business), 2014-2017
R & D Expenditure of Porton Fine Chemical and % of Total Revenue, 2014-2017 
Revenue and Net Income of Porton Fine Chemical, 2016-2021E
Revenue and Net Income of JOINN Laboratories, 2014-2016 
Revenue of JOINN Laboratories (by Business), 2014-2016
Revenue Structure of JOINN Laboratories (by Business), 2014-2016
Gross Margin of JOINN Laboratories, 2014-2016 
R & D Expenditure of JOINN Laboratories and % of Total Revenue, 2014-2016 
Investment Projects of JOINN Laboratories by Raising Funds via IPO, 2017 
JOINN Laboratories’ Revenue from Top 5 Clients and % of Total Revenue, 2014-2016
Revenue and Net Income of JOINN Laboratories, 2016-2021E
Pharmaron’s Revenue and Net Income, 2014-2016 
Pharmaron’s Revenue (by Business), 2014-2016
Pharmaron’s Gross Margin (by Business), 2014-2016
Composition of Pharmaron’s R & D Division 
Pharmaron’s Staff Structure by Division
Pharmaron’s M&A Cases, 2015-2017
Pharmaron’s Investment Projects by Raising Funds via IPO, 2017 
Pharmaron’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2016  
Pharmaron’s Revenue and Net Income, 2016-2021E  
Revenue and Net Income of Obio Technology (Shanghai), 2014-2017
Revenue of Obio Technology (Shanghai) (by Business), 2014-2017 
Revenue Structure of Obio Technology (Shanghai) (by Business), 2014-2017 
Gross Margin of Obio Technology (Shanghai), 2014-2017 
R & D Expenditure of Obio Technology (Shanghai) and % of Total Revenue, 2014-2017 
Obio Technology (Shanghai)’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2016  
Revenue and Net Income of Obio Technology (Shanghai), 2016-2021E  
Revenue and Net Income of Asymchem Laboratories, 2013-2017 
Operating Revenue of Asymchem Laboratories (by Business), 2013-2017
Operating Revenue Structure of Asymchem Laboratories (by Business), 2013-2017
Revenue of Asymchem Laboratories (by Region), 2015-2017
Revenue Structure of Asymchem Laboratories (by Region), 2015-2017
Gross Margin of Asymchem Laboratories’ Main Business, 2013-2017 
R & D Expenditure of Asymchem Laboratories and % of Total Revenue, 2014-2017 
Investment Projects of Asymchem Laboratories by Raising Funds via IPO, 2016 
Asymchem Laboratories’ Revenue from Top 5 Clients and % of Total Revenue, 2014-2016  
Revenue and Net Income of Asymchem Laboratories, 2016-2021E
Equity Structure of Shanghai ChemPartnert’s Subsidiaries
Main Content of Shanghai ChemPartnert’s CRO Business
Main Content of Shanghai ChemPartnert’s CMO Business
Revenue of Shanghai ChemPartner (by Business)  
Revenue of Shanghai ChemPartner (by Region)
Shanghai ChemPartnert’s Revenue from Major Customers and % of Total Revenue, 2015-2017 
LabCorp’s Revenue and Net Income, 2013-2017  
LabCorp’s Revenue (by Division), 2013-2017 
LabCorp’s Revenue Structure (by Division), 2013-2017 
LabCorp’s CRO Revenue and % of Total Revenue, 2015-2017 
Revenue and Net Income of QuintilesIMS, 2014-2017
Operating Revenue of QuintilesIMS (by Division), 2014-2017 
Operating Revenue Structure of QuintilesIMS (by Division), 2014-2017 
Parexel’s Revenue and Net Income, FY2014-2017 
Parexel’s Operating Revenue (by Division), FY2014-2017
Parexel’s Operating Revenue Structure (by Division), FY2014-2017 
Parexel’s Branches in China by H1 2017 
Revenue and Net Income of Charles River, 2014-2017
Revenue of Charles River (by Division), 2014-2017 
Revenue Structure of Charles River (by Division), 2014-2017 

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号